Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
Clinical trial NCT03967223 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03967223
- Sponsor
- USWM CT, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-31
- Primary completion
- 2024-03-01
- Enrollment
- 103
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.